Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Claudia Sargas,Rosa Ayala,María J Larráyoz,María C Chillón,Eduardo Rodriguez-Arboli,Cristina Bilbao,Esther Prados de la Torre,David Martínez-Cuadrón,Rebeca Rodríguez-Veiga,Blanca Boluda,Cristina Gil,Teresa Bernal,Juan Bergua,Lorenzo Algarra,Mar Tormo,Pilar Martínez-Sánchez,Elena Soria,Josefina Serrano,Juan M Alonso-Dominguez,Raimundo García,María Luz Amigo,Pilar Herrera-Puente,María J Sayas,Esperanza Lavilla-Rubira,Joaquín Martínez-López,María J Calasanz,Ramón García-Sanz,José A Pérez-Simón,María T Gómez Casares,Joaquín Sánchez-García,Eva Barragán,Pau Montesinos,PETHEMA cooperative study group
DOI: https://doi.org/10.1038/s41408-023-00835-5
2023-05-12
Abstract:Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged ≥65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with ≥2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 ± complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines.
What problem does this paper attempt to address?